Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients

NCT ID: NCT05557240

Last Updated: 2022-10-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-13
• Study Completion Date: 2025-08-12

Brief Summary

The primary objective of this study is to assess the safety and tolerability, feasibility of the NeoPep Vaccine in newly diagnosed glioblastoma (GB) patients.

Detailed Description

This is a signelcenter, open-label, single arm, first-in-human phase I trial to investigate the safety, feasibility and immune response of the novel NeoPep Vaccine in patients with newly diagnosed GB.

Primary Endpoints:

Determine the safety and tolerability profile of NeoPep Vaccine1and 2 when administered with immunomodulators and Stupp standard treatment

Secondry Endpoints:

1. Descriptive analysis of induced T-cell immune responses after vaccinations with NeoPep Vaccine1and 2 drug products plus immunomodulators and Stupp standard treatment.

2. Overall survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp.

3. Progression-free survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp.

After the standard chemoradiotherapy with TMZ has been completed, Vaccination was initiated 14 days before the first maintenanceTMZ cycle. It starts with the first NeoPep Vaccine1, followed by additional NeoPep Vaccine2 at a later time point and ends with the Last Endpoint Evaluation Visit (LEEV) of a patient.

Conditions

Glioma, Malignant; Antigen-specific Vaccines; Individualized Treatment

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

NeoPep Vaccine1and 2 plus polyICLC concurrent to TMZ

Group Type: EXPERIMENTAL

NeoPep Vaccine1 plus Poly-ICLC

Intervention Type: DRUG

NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used.

Poly-ICLC:

Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations.

NeoPep Vaccine2 plus Poly-ICLC

Intervention Type: DRUG

NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used.

Poly-ICLC:

Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations.

Interventions

NeoPep Vaccine1 plus Poly-ICLC

NPVAC1： NPVAC1 drug products are composed of 5 peptides from the HCMV warehouse， NPVAC1 vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with NPVAC1 drug products during 6 weeks. 400 μg per peptide per vial are used.

Poly-ICLC:

Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations.

Intervention Type: DRUG

NeoPep Vaccine2 plus Poly-ICLC

NPVAC2： NPVAC2 will be ready for use 2 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. NPVAC2 drug products are composed 20 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with NPVAC2 drug products beginning on day 33 of the 6 maintenance TMZ cycle.Patients will receive 9 vaccinations within 12 weeks. 400 μg per peptide per vial are used.

Poly-ICLC:

Poly-ICLC（500ug）will be used as immunomodulator with all vaccinations.

Intervention Type: DRUG

Other Intervention Names

NPVAC1+Poly-ICLC; NPVAC2+Poly-ICLC

Eligibility Criteria

Inclusion Criteria

1. Ability of subject to understand and the willingness to sign written informed consent for study participation;

2. Patients with newly diagnosed high-grade glioma confirmed by histopathological and imaging evaluation;

3. Gross total resection (as defined by less than 1 cm2 residual tumor mass on the largest perpendicular axes in post-operative scan taken within 48 h post-surgery; standard MRI conformable to the present national and international guidelines is sufficient)；

4. At least 0.5 g tumor tissue freshly cryopreserved during surgery，and could provide adequate amounts of PBMC；

5. Patient is a candidate for and willing to receive standard CRT with TMZ followed by maintenance TMZ cycles;

6. Age 18-70;

7. Life expectancy > 9 months;

8. KPS≥70;

9. Sufficient tumor tissue samples and peripheral blood samples can be obtained for sequencing analysis, or whole exome sequencing and RNA sequencing of tumor tissue samples and peripheral blood samples have been obtained, and the sequencing data meet the prediction requirements;

10. Consent of women and men of reproductive age to use adequate and effective contraception during clinical trials;

1. White blood cell count (WBC) ≥3.0×109/L；

2. Absolutely neutrophil count≥1.0×109/L；

3. Platelet count≥80×109/L；

4. Hemoglobin content≥90g/L；

5. Serum creatinine≤1.5 ULN or Creatinine clearance rate≥40 mL/min;

6. TBil(total bilirubin)≤1.5 x ULN;

7. Aspartic transaminase(AST)≤2.5x ULN or Alanine aminotransferase（ALT）≤2.5x ULN；Patients with liver metastases must have ≤5x ULN;

8. Blood coagulation function :INR≤1.5x ULN；pT and APTT≤1.5x ULN;

9. Urine protein< 2 +;if Urine protein≥2+,24-hour urinary protein must be less than 1g.

Exclusion Criteria

1. Patients treated with immunosuppressive agents (e.g., cyclosporin CsA, tacrolimus, rapamycin, azathioprine, etc.) within the previous month; Other immunotherapy within 3 months;

2. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 5 years unless the patient has been disease-free for 5 years;

3. Participated in other clinical trials within 30 days prior to screening;

4. Have a history of severe allergy or allergic constitution;

5. Patients who have undergone splenectomy;

6. Persons with primary or secondary immunodeficiency diseases (e.g. AIDS);Patients with autoimmune diseases;

7. Patients who received multiple oral, intramuscular, or intravenous corticosteroids within 30 days before the first dose; However, patients who received a single oral, intramuscular, or intravenous dose of dexamethasone of 5mg or less (or another hormone of equivalent potency) 14 days before the first dose were allowed; Allow inhaled corticosteroids to treat respiratory insufficiency (e.g., chronic obstructive pulmonary disease), or topical steroids;

8. Patients with uncontrollable seizures, central nervous system disorders, or psychotic loss of cognition;

9. Uncontrolled central nervous system metastases;

10. Patients had a history of chronic alcohol or drug abuse in the 6 months before screening;

11. With unstable systemic disease, such as active infection, liver cirrhosis, chronic renal failure, severe chronic pulmonary disease, unstable hypertension, unstable angina pectoris, congestive heart failure, myocardial infarction within one year, etc. ;

12. According to this procedure, the number of candidate neoantigens that can be used to make personalized vaccines is less than 20;

13. The investigator did not consider it appropriate to participate in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hangzhou NeoVax Biotechnology Co. Ltd.

INDUSTRY

Sponsor Role: collaborator

Shanghai 10th People's Hospital

OTHER

Sponsor Role: lead

Responsible Party

LiangGao

Neurosurgery department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Liang Gao, Phd

Role: PRINCIPAL_INVESTIGATOR

Shanghai 10th People's Hospital

Locations

Shanghai 10th People's Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Lei Li, Phd

Role: CONTACT

Lei-Li@alumni.tongji.edu.cn

18817952194

Facility Contacts

Liang Gao, Phd

Role: primary

lianggaoh@126.com

13817934652

Other Identifiers

10247

Identifier Type: -

Identifier Source: org_study_id